Qishenyiqi Dripping Pill for Coronary Microvascular Disease

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Coronary Microvascular Disease

In brief

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Key facts

Study ID
NCT06699420
Run by
Qilu Hospital of Shandong University
People needed
162
Starts
2023-11-08
Expected to finish
2026-06-30
Last updated by the study team
2024-11-21

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.